Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERM NASDAQ:EDSA NASDAQ:EVAX NASDAQ:IPHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.25-0.1%$5.78$4.31▼$9.56$170.62M1.03203,921 shs2,113 shsEDSAEdesa Biotech$10.54+17.1%$8.64$0.72▼$20.32$90.49M1.263.07 million shs256,966 shsEVAXEvaxion A/S$4.06-0.9%$4.00$1.67▼$12.15$33.82M0.2641,800 shs2,200 shsIPHAInnate Pharma$2.12-5.7%$1.47$1.17▼$2.63$202.96M0.2250,118 shs26,228 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical-1.26%+25.00%+15.96%-22.84%-9.81%EDSAEdesa Biotech-31.03%-41.10%+51.77%+778.05%+343.35%EVAXEvaxion A/S+4.34%-3.08%-8.09%+29.43%+134.87%IPHAInnate Pharma+11.39%+58.45%+35.54%+33.14%+6.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$6.25-0.1%$5.78$4.31▼$9.56$170.62M1.03203,921 shs2,113 shsEDSAEdesa Biotech$10.54+17.1%$8.64$0.72▼$20.32$90.49M1.263.07 million shs256,966 shsEVAXEvaxion A/S$4.06-0.9%$4.00$1.67▼$12.15$33.82M0.2641,800 shs2,200 shsIPHAInnate Pharma$2.12-5.7%$1.47$1.17▼$2.63$202.96M0.2250,118 shs26,228 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical-1.26%+25.00%+15.96%-22.84%-9.81%EDSAEdesa Biotech-31.03%-41.10%+51.77%+778.05%+343.35%EVAXEvaxion A/S+4.34%-3.08%-8.09%+29.43%+134.87%IPHAInnate Pharma+11.39%+58.45%+35.54%+33.14%+6.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 2.25Hold$13.00108.17% UpsideEDSAEdesa Biotech 2.00Hold$5.00-52.57% DownsideEVAXEvaxion A/S 2.67Moderate Buy$11.00171.27% UpsideIPHAInnate Pharma 2.50Moderate Buy$5.00135.74% UpsideCurrent Analyst Ratings BreakdownLatest EVAX, DERM, EDSA, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026EVAXEvaxion A/S HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.004/21/2026IPHAInnate Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026DERMJourney Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026IPHAInnate Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/27/2026EDSAEdesa Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/26/2026DERMJourney Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.003/12/2026IPHAInnate Pharma BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$8.003/11/2026IPHAInnate Pharma BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/10/2026EVAXEvaxion A/S JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$10.003/9/2026EVAXEvaxion A/S Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.00 ➝ $9.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$61.86M2.76N/AN/A$0.96 per share6.51EDSAEdesa BiotechN/AN/AN/AN/A$0.45 per shareN/AEVAXEvaxion A/S$7.53M4.49N/AN/A$2.04 per share1.99IPHAInnate Pharma$10.19M19.55N/AN/A($0.26) per share-8.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$11.43M-$0.37N/A4.31N/A-14.82%-35.57%-10.88%N/AEDSAEdesa Biotech-$7.19M-$1.34N/AN/AN/AN/A-286.52%-75.36%N/AEVAXEvaxion A/S-$7.71M-$1.47N/A0.74N/AN/A-73.56%-37.45%N/AIPHAInnate Pharma-$55.64MN/AN/AN/AN/AN/AN/AN/AN/ALatest EVAX, DERM, EDSA, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q2 2026EDSAEdesa Biotech-$0.24-$0.49-$0.25-$0.49$0.05 million$0.05 million5/13/2026Q1 2026DERMJourney Medical-$0.07-$0.08-$0.01-$0.08$15.47 million$15.96 million5/7/2026Q1 2026EVAXEvaxion A/S-$0.01-$0.44-$0.43-$0.10$9.20 millionN/A3/25/2026Q4 2025DERMJourney Medical-$0.06-$0.04+$0.02-$0.04$18.86 million$16.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical0.741.721.47EDSAEdesa BiotechN/A4.764.76EVAXEvaxion A/S0.415.855.85IPHAInnate PharmaN/A1.271.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%EDSAEdesa Biotech5.50%EVAXEvaxion A/S11.04%IPHAInnate Pharma0.16%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%EDSAEdesa Biotech24.40%EVAXEvaxion A/S41.64%IPHAInnate Pharma31.89%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9027.33 million23.22 millionN/AEDSAEdesa Biotech208.89 million6.72 millionNot OptionableEVAXEvaxion A/S608.34 million4.87 millionNo DataIPHAInnate Pharma22093.92 million63.97 millionNot OptionableEVAX, DERM, EDSA, and IPHA HeadlinesRecent News About These CompaniesInnate Pharma S.A. (NASDAQ:IPHA) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comInnate Pharma Q1 Earnings Call HighlightsMay 13, 2026 | marketbeat.comInnate Pharma Reports First Quarter 2026 Business Update and Financial ResultsMay 13, 2026 | businesswire.comNumber of Shares and Voting Rights of Innate Pharma as of April 16, 2026May 12, 2026 | businesswire.comInnate Pharma (IPHA) Projected to Post Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comInnate Pharma (IPHA) Expected to Announce Quarterly Earnings on WednesdayMay 6, 2026 | marketbeat.comInnate Pharma Announces Conference Call and Webcast for Q1 2026 Business UpdateMay 6, 2026 | businesswire.comInnate Pharma (NASDAQ:IPHA) Shares Down 0.7% - Here's What HappenedMay 4, 2026 | marketbeat.comInnate Pharma SA: Innate Pharma to Participate in the D. Boral Capital Global ConferenceApril 23, 2026 | finanznachrichten.deInnate Pharma to Participate in the D. Boral Capital Global ConferenceApril 23, 2026 | businesswire.comInnate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026April 17, 2026 | businesswire.comNumber of Shares and Voting Rights of Innate Pharma as of April 9, 2026April 13, 2026 | businesswire.comInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026April 13, 2026 | businesswire.comInnate Pharma SA Sponsored ADRApril 8, 2026 | edition.cnn.comInnate Pharma to Present at the AACR 2026 Oncology Industry Partnering EventApril 8, 2026 | businesswire.comInnate Pharma to Participate in the Kempen Life Sciences ConferenceApril 3, 2026 | businesswire.comInnate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual ReportApril 2, 2026 | businesswire.comInnate Pharma S.A. (IPHA) Q4 2025 Earnings Call TranscriptMarch 26, 2026 | seekingalpha.comInnate ends work on NK cell engager in phase 1/2 trial as part of ongoing pipeline refocusMarch 26, 2026 | fiercebiotech.comFInnate Pharma SA: Innate Pharma Reports Full Year 2025 Financial Results and Business UpdateMarch 26, 2026 | finanznachrichten.deInnate Pharma Reports Full Year 2025 Financial Results and Business UpdateMarch 26, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVAX, DERM, EDSA, and IPHA Company DescriptionsJourney Medical NASDAQ:DERM$6.24 -0.01 (-0.08%) As of 10:09 AM Eastern This is a fair market value price provided by Massive. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.Edesa Biotech NASDAQ:EDSA$10.54 +1.54 (+17.13%) As of 10:10 AM Eastern This is a fair market value price provided by Massive. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Evaxion A/S NASDAQ:EVAX$4.06 -0.04 (-0.86%) As of 10:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Innate Pharma NASDAQ:IPHA$2.12 -0.13 (-5.73%) As of 10:09 AM Eastern This is a fair market value price provided by Massive. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dillard’s Posted a Huge Earnings Beat—So Why Did the Rally Fade? Why Trump’s Amazon Stock Sale May Not Matter at All Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
